4 results about "Biodegradable nanoparticles" patented technology

The present disclosure features imaging media including a contrast agent encapsulated within a biodegradable nanoparticle matrix. The particles are sized such that they avoid excretion via urinary excretion (e.g., at least 5 nm in diameter) during an imaging procedure or an image-guided procedure. Instead, the particles are predominantly removed from circulation by the reticuloendothelial system of the liver. This results in a buildup of contrast agent in the liver, allowing for a highly specific imaging modality for liver imaging. Further, the bulk of the imaging media is excreted into the bowel, reducing in-vivo toxicity of the imaging media. Finally, because of their size, the nanoparticles of the imaging media have a higher circulation half-life.

This invention discloses a topologically oriented cyclodextrin / chitosan composite membrane, its preparation method, and its applications, belonging to the field of bio-based nanomaterials technology. Using α-cyclodextrin and polyethylene glycol (PEG) as raw materials, this invention prepares topologically oriented cyclodextrin-PEG "ring-slippery" nanoparticles (TNPs). TNPs, as green and biodegradable nanoparticles, fill the chitosan network matrix, enhancing hydrogen bonding interactions with chitosan molecules and improving the mechanical properties of the chitosan membrane. This method not only uses simple raw materials and is easy to implement, but also effectively improves the mechanical strength of the chitosan composite membrane, effectively overcoming the problem of poor mechanical strength in existing chitosan composite membranes, and providing a simple and effective approach for practical production.

Functionalized nanoparticle composition comprising 5-fluorouracil for enhanced anticancer activity, the composition comprising: a. 5-Fluorouracil at a quantity of 10.00% w / w, configured as an active anticancer agent; b. Poly(lactic acid-co-glycolic acid) at a quantity of 60.00% wt / w, configured to encapsulate the 5-fluorouracil and form a biodegradable nanoparticle matrix; c. Polyethylene glycol (PEG-2000) in an amount of 10.00% (w / w) configured to functionalize the surface of the nanoparticles and improve stability and bioavailability; d. Chitosan at a quantity of 5.00% (wt / wt), configured to effect surface modification and improve cellular uptake and targeting accuracy; e. Polyvinyl alcohol in an amount of 3.00% wt / wt, configured as a stabilizing and emulsifying agent during nanoparticle formation; f. Tween 80 at a concentration of 2.00% w / w, configured to improve dispersion stability and control particle size; and g. Mannitol at a quantity of 10.00% w / w, configured as a cryoprotectant to enhance stability during lyophilization and storage; the composition offering improved drug incorporation efficiency, delayed drug release, improved bioavailability, and enhanced anticancer activity compared to non-functionalized formulations of 5-fluorouracil.

Described are new biodegradable nanoparticle platforms for encapsulation and sustained release of protein therapeutics through a scalable and reproducible method. Specifically nanoparticles comprising a complex comprising a protein, or peptide, and a counter ion polymer are described.